

Update Summary

New Test Activation	11/18/2025	<u>B27M - "HLA-B27 Identification by PCR"</u>
Update Existing Test	11/4/2025	<u>COADP - "Complete Atopic Dermatitis Panel"</u>
Update Existing Test	11/4/2025	<u>HMGCR - "HMGCR Antibody IgG"</u>
Update Existing Test	11/4/2025	<u>OBFIT - "Fecal Immunochemical Test for Occult Blood"</u>
Update Existing Test	11/4/2025	<u>PHBF - "pH, Body Fluid"</u>
Update Existing Test	11/4/2025	<u>RUBEM - "Measles (Rubeola) IgM Antibody"</u>
Update Existing Test	11/4/2025	<u>TMSI - "Microsatellite Instability, Tumor"</u>
Update Existing Test	12/1/2025	<u>UPHEP - "Phenol Exposure, Urine"</u>
Inactivate Test With Replacement	11/4/2025	<u>GRAN - "Granulocyte Antibodies, Serum" replaced by GRANS - "Granulocyte Antibody Screen, Serum"</u>
Inactivate Test Without Replacement	11/4/2025	<u>MUMPM - "Mumps Virus Antibody IgM"</u>
Inactivate Test Without Replacement	11/3/2025	<u>UBSP - "Bath Salts Panel (Qualitative), Urine"</u>

New Test Activation

Effective Date	11/18/2025
Name	HLA-B27 Identification by PCR
Code	B27M
CPT Code(s)	81374
Notes	New York DOH Approval Status: No

Specimen Requirements

Specimen Required	<i>Collect:</i> Lavender EDTA <i>Specimen Preparation:</i> Draw blood in a lavender EDTA. Send 4.0 mL whole blood. <i>Minimum Volume:</i> 0.5 mL <i>Transport Temperature:</i> Refrigerated
Alternate Specimen	Whole blood: ACD A
Rejection Criteria	Serum, plasma, heparinized whole blood, tissue
Stability	Room temperature: 3 days Refrigerated: 7 days Frozen: 30 days

Performing Information

Methodology	Polymerase Chain Reaction (PCR)
Reference Range	See report
Performed Days	Monday, Thursday
Turnaround Time	3 - 5 days
Performing Laboratory	Warde Medical Laboratory

Interface Information

Legacy Code	B27M		
Interface Order Code	3000462		
Result Code	Name	LOINC Code	AOE/Prompt
3000463	HLA-B27 Allele		No

QC ACCOUNT (WARDE)
 300 W. TEXTILE
 ANN ARBOR MI 48108

EXAMPLE, REPORT

WX0000000237 F 12/05/1988 36 Y

Molecular					
	Result	Collected: 10/14/2025 10:29	Received: 10/14/2025 10:29		
<u>Test Name</u>	<u>Result</u>	<u>Flag</u>	<u>Ref-Ranges</u>	<u>Units</u>	<u>Site</u>
HLA-B27 Identification by PCR					
HLA-B27 Allele	DETECTED	AB			WMRL
BACKGROUND:	Presence of the HLA-B27 allele is strongly associated with ankylosing spondylitis (AS), Reiter syndrome, anterior uveitis, psoriatic arthritis, and inflammatory bowel disease.				
PREVALENCE:	The HLA-B27 allele can be found in 8% of Caucasians but varies regionally. The allele frequency is 25% in Northern Scandinavia, 2-8% in Southern Europe, North Africa and China, and <0.5% in Japanese.				
INCIDENCE:	>90% of patients with AS are HLA-B27 positive compared to 5-10% of the general population.				
PENETRANCE:	2-8% of individuals with at least one copy of the HLA-B27 allele will develop AS.				
METHODOLOGY:	Polymerase chain reaction (PCR) and melt curve analysis (MCA).				
ASSAY PERFORMANCE:	>95% clinical sensitivity. >99% clinical specificity. LOD >1 ng gDNA. No cross-reactivity with any other HLA-B alleles has been observed.				
LIMITATIONS:	The primers are expected to miss the following HLA-B27 allele subtypes: B*27:04:03, B*27:07:01, B*27:07:02, B*27:07:03, B*27:07:04, B*27:102, B*27:11, B*27:125, B*27:14, B*27:19, B*27:20, B*27:21, B*27:24, B*27:30, B*27:32, B*27:33, B*27:34, B*27:36, B*27:43, B*27:70, B*27:81, B*27:90:01, B*27:90:02.				
This test was developed and its performance characteristics determined by Warde Medical Laboratory. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.					
Reported Date: 10/14/2025 10:29 B27M Performing Site: WMRL: WARDE MEDICAL LABORATORY 300 West Textile Road Ann Arbor MI 48108					

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

 E214000002
 WX0000000237
 Printed D&T: 10/14/25 10:29

 Ordered By: CLIENT CLIENT
 WX000000000000336

 Kajal V. Sitwala, MD, PhD - Medical Director
 Form: MM RL1
 PAGE 1 OF 1

Update Existing Test

Effective Date	11/4/2025
Name	Complete Atopic Dermatitis Panel
Code	COADP
Interface Order Code	3300367
Legacy Code	COADP
Notes	Update to turnaround time.

Required Testing Changes

Turnaround Time	12 - 14 days
------------------------	--------------

Update Existing Test

Effective Date	11/4/2025
Name	HMGCR Antibody IgG
Code	HMGCR
Interface Order Code	3600035
Legacy Code	HMGCR
Notes	Update to CPT code, stability, methodology, reference range, performed days, and turnaround time.

Required Testing Changes

CPT Code(s)	82397
Stability	Room temperature: 48 hours Refrigerated: 14 days Frozen: 30 days (avoid repeated freeze/thaw cycles)
Methodology	Semi-quantitative Chemiluminescent Immunoassay (CLIA)
Reference Range	Less than 20.0
Performed Days	Monday, Wednesday, Friday
Turnaround Time	3 - 7 days

Update Existing Test

Effective Date	11/4/2025
Name	Fecal Immunochemical Test for Occult Blood
Code	OBFIT
Interface Order Code	3000894
Legacy Code	OBFIT
Notes	Update to rejection criteria and stability.

Required Testing Changes

Rejection Criteria	Unpreserved stool; Specimens received >15 days from date of collection
Stability	Room temperature: 15 days Refrigerated: 15 days Frozen: Unacceptable

Update Existing Test

Effective Date	11/4/2025
Name	pH, Body Fluid
Code	PHBF
Interface Order Code	3619600
Legacy Code	PHBF
Notes	Update to specimen requirements.

Required Testing Changes

Specimen Required	<p><i>Collect:</i> Body fluid</p> <p><i>Specimen Preparation:</i> Send 5.0 mL of well-mixed body fluid in a sterile screw capped plastic vial.</p> <p>Indicate specimen source.</p> <p><i>Minimum Volume:</i> 1.0 mL</p> <p><i>Transport Temperature:</i> Refrigerated</p>
--------------------------	---

Update Existing Test

Effective Date	11/4/2025
Name	Measles (Rubeola) IgM Antibody
Code	RUBEM
Interface Order Code	3685580
Legacy Code	RUBEMAR
Notes	Update to specimen requirements, rejection criteria, stability, methodology, and reference range.

Required Testing Changes

Specimen Required	<p><i>Collect:</i> Serum Separator Tube (SST)</p> <p><i>Specimen Preparation:</i> Centrifuge, separate serum from cells within 2 hours, and send 0.5 mL serum in a screw capped plastic vial. Parallel testing is preferred and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as "acute" or "convalescent".</p> <p><i>Minimum volume:</i> 0.3 mL</p> <p><i>Transport Temperature:</i> Refrigerated</p>
Rejection Criteria	Bacterially contaminated, heat-inactivated, hemolyzed, icteric, lipemic, or turbid specimens.
Stability	<p>Room temperature: 48 hours</p> <p>Refrigerated: 14 days</p> <p>Frozen: 30 days (avoid repeated freeze/thaw cycles)</p>
Methodology	Semi-quantitative Indirect Fluorescent Antibody (IFA)
Reference Range	Less than 1:10

Update Existing Test

Effective Date	11/4/2025
Name	Microsatellite Instability, Tumor
Code	TMSI
Interface Order Code	3800241
Legacy Code	TMSI
Notes	Update to specimen requirements, alternate specimen, stability, and performed days.

Required Testing Changes

Specimen Required	<p>Patient Preparation: Pathology report must accompany specimen in order for testing to be performed. This assay requires at least 40% tumor nuclei for endometrial specimens and at least 20% tumor nuclei for colorectal specimens.</p> <p>Collect: Tissue block</p> <p>Specimen Preparation: Send a formalin-fixed paraffin embedded tissue block, (non-decalcified), with approximately 72 mm(2) area of tumor.</p> <p>Minimum Volume: 18 mm(2) area of tumor</p> <p>Transport Temperature: Room temperature</p>
Alternate Specimen	<p>Tissue slide: 1 Slide stained with hematoxylin and eosin and 10 Unstained, nonbaked slides with 5-micron thick sections of the tumor tissue.</p> <p>Note: The total amount of required tumor nuclei can be obtained by scraping up to 10 slides from the same block. Unused unstained slides will not be returned.</p>
Stability	<p>Room temperature: Indefinitely</p> <p>Refrigerated: Unacceptable</p> <p>Frozen: Unacceptable</p>
Performed Days	Varies

Update Existing Test

Effective Date	12/1/2025
Name	Phenol Exposure, Urine
Code	UPHEP
Interface Order Code	3301475
Legacy Code	UPHEP
Notes	Update to CPT code and methodology.

Required Testing Changes

CPT Code(s)	82570
Methodology	Colorimetry

Inactivate Test With Replacement

Effective Date	11/4/2025
-----------------------	-----------

Inactivated Test

Name	Granulocyte Antibodies, Serum
Code	GRAN
Legacy Code¹	GRANABM
Interface Order Code	3801950

Replacement Test

Name	Granulocyte Antibody Screen, Serum
Code	GRANS
CPT Code(s)	86021 x2
Notes	New York DOH Approval Status: Yes

Specimen Requirements

Specimen Required	<i>Patient Preparation:</i> Only a specimen collected before a transfusion reaction is acceptable. <i>Collect:</i> Red top <i>Specimen Preparation:</i> Centrifuge, separate and send 1.5 mL serum refrigerated in a screw capped plastic vial. <i>Minimum Volume:</i> 0.3 mL <i>Transport Temperature:</i> Refrigerated
Rejection Criteria	Serum separator tube (SST), gross hemolysis
Stability	Room temperature: 7 days Refrigerated: 30 days Frozen: 1 year

Performing Information

Methodology	Flow Cytometry/Agglutination
Reference Range	Negative
Performed Days	Tuesday, Thursday
Turnaround Time	9 - 17 days
Performing Laboratory	Mayo Clinic Laboratories

Interface Information

Legacy Code	GRANS		
Interface Order Code	3800422		
Result Code	Name	LOINC Code	AOE/Prompt
3800423	GIFT/GAT Interpretation	105288-5	No
3800424	GIFT Result	105286-9	No
3800426	GAT Result	105287-7	No



LABORATORY REPORT

QC ACCOUNT (WARDE)
300 W. TEXTILE
ANN ARBOR MI 48108

EXAMPLE, REPORT

WX0000000237 F 12/05/1988 36 Y

Referral Testing

Collected: 10/16/2025 11:10 Received: 10/16/2025 11:10

Test Name	Result	Flag	Ref-Ranges	Units	Site
-----------	--------	------	------------	-------	------

Granulocyte Antibody Screen, Serum

GIFT/GAT Interpretation

SEE BELOW

MMRL

RESULT: No granulocyte antibody reactivity was detected.

GIFT Result

Negative

MMRL

-----ADDITIONAL INFORMATION-----

Method: Flow Cytometry

GAT Result

Negative

MMRL

-----ADDITIONAL INFORMATION-----

Method: Agglutination Test

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CLIA: 24D0404292 CLIA Lab Director: NIKOLA BAUMANN, Ph.D.

Test Performed by:

Mayo Clinic Laboratories - Rochester Main Campus
200 First Street SW, Rochester, MN 55905
Lab Director: Nikola A. Baumann Ph.D.; CLIA# 24D0404292

Reported Date: 10/16/2025 11:13 GRANS

Performing Site:

MMRL: MAYO MEDICAL REFERENCE LAB 3050 Superior Drive NW Rochester MN 55901

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

E216000001
WX0000000237
Printed D&T: 10/16/25 11:14

Ordered By: CLIENT CLIENT
WX000000000000511

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 1 OF 1

Inactivate Test Without Replacement

Effective Date	11/4/2025
Name	Mumps Virus Antibody IgM
Code	MUMPM
Legacy Code	MUMPSMARP
Interface Code	3620660
Notes	Test discontinued.

Inactivate Test Without Replacement

Effective Date	11/3/2025
Name	Bath Salts Panel (Qualitative), Urine
Code	UBSP
Legacy Code	UBSP
Interface Code	3300132
Notes	Test discontinued.